Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Endocrinol ; 232(3): 437-450, 2017 03.
Article in English | MEDLINE | ID: mdl-28057868

ABSTRACT

Corticosteroids directly affect the heart and vasculature and are implicated in the pathogenesis of heart failure. Attention is focussed upon the role of the mineralocorticoid receptor (MR) in mediating pro-fibrotic and other adverse effects of corticosteroids upon the heart. In contrast, the role of the glucocorticoid receptor (GR) in the heart and vasculature is less well understood. We addressed this in mice with cardiomyocyte and vascular smooth muscle deletion of GR (SMGRKO mice). Survival of SMGRKO mice to weaning was reduced compared with that of littermate controls. Doppler measurements of blood flow across the mitral valve showed an elongated isovolumetric contraction time in surviving adult SMGRKO mice, indicating impairment of the initial left ventricular contractile phase. Although heart weight was elevated in both genders, only male SMGRKO mice showed evidence of pathological cardiomyocyte hypertrophy, associated with increased myosin heavy chain-ß expression. Left ventricular fibrosis, evident in both genders, was associated with elevated levels of mRNA encoding MR as well as proteins involved in cardiac remodelling and fibrosis. However, MR antagonism with spironolactone from birth only modestly attenuated the increase in pro-fibrotic gene expression in SMGRKO mice, suggesting that elevated MR signalling is not the primary driver of cardiac fibrosis in SMGRKO mice, and cardiac fibrosis can be dissociated from MR activation. Thus, GR contributes to systolic function and restrains normal cardiac growth, the latter through gender-specific mechanisms. Our findings suggest the GR:MR balance is critical in corticosteroid signalling in specific cardiac cell types.


Subject(s)
Muscle, Smooth, Vascular/metabolism , Myocytes, Cardiac/metabolism , Receptors, Glucocorticoid/metabolism , Animals , Corticosterone/blood , Female , Fibrosis/metabolism , Fibrosis/pathology , Male , Mice , Mice, Knockout , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/pathology , Myocardial Contraction/genetics , Myocardium/metabolism , Myocardium/pathology , Myocytes, Cardiac/drug effects , Myocytes, Cardiac/pathology , Myosin Heavy Chains/genetics , Myosin Heavy Chains/metabolism , Nonmuscle Myosin Type IIB/genetics , Nonmuscle Myosin Type IIB/metabolism , Receptors, Glucocorticoid/genetics , Sex Factors , Spironolactone/pharmacology , Ventricular Function, Left/genetics
2.
Development ; 143(20): 3686-3699, 2016 10 15.
Article in English | MEDLINE | ID: mdl-27578791

ABSTRACT

Insufficient alveolar gas exchange capacity is a major contributor to lung disease. During lung development, a population of distal epithelial progenitors first produce bronchiolar-fated and subsequently alveolar-fated progeny. The mechanisms controlling this bronchiolar-to-alveolar developmental transition remain largely unknown. We developed a novel grafting assay to test if lung epithelial progenitors are intrinsically programmed or if alveolar cell identity is determined by environmental factors. These experiments revealed that embryonic lung epithelial identity is extrinsically determined. We show that both glucocorticoid and STAT3 signalling can control the timing of alveolar initiation, but that neither pathway is absolutely required for alveolar fate specification; rather, glucocorticoid receptor and STAT3 work in parallel to promote alveolar differentiation. Thus, developmental acquisition of lung alveolar fate is a robust process controlled by at least two independent extrinsic signalling inputs. Further elucidation of these pathways might provide therapeutic opportunities for restoring alveolar capacity.


Subject(s)
Epithelial Cells/cytology , Epithelial Cells/metabolism , Glucocorticoids/metabolism , Lung/cytology , Lung/metabolism , Stem Cells/cytology , Stem Cells/metabolism , Adenoviridae/genetics , Alveolar Epithelial Cells/cytology , Alveolar Epithelial Cells/metabolism , Animals , Cell Differentiation/drug effects , Cell Differentiation/genetics , Cells, Cultured , Glucocorticoids/antagonists & inhibitors , Humans , Mice , Mifepristone/pharmacology , Pulmonary Alveoli/cytology , Pulmonary Alveoli/metabolism , Reverse Transcriptase Polymerase Chain Reaction , STAT3 Transcription Factor/genetics , STAT3 Transcription Factor/metabolism , Signal Transduction/drug effects , Signal Transduction/genetics
3.
Trends Endocrinol Metab ; 27(1): 35-43, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26586027

ABSTRACT

The efficacy of mineralocorticoid receptor (MR) antagonism in the treatment of certain patients with heart failure has highlighted the pivotal role of aldosterone and MR in heart disease. The glucocorticoid (GC) receptor (GR) is also expressed in heart, but the role of cardiac GR had received much less attention until recently. GR and MR are highly homologous in both structure and function, although not in cellular readout. Recent evidence in animal models has uncovered a tonic role for GC action via GR in cardiomyocytes in prevention of heart disease. Here, we review this evidence and the implications for a balance between GR and MR activation in the early life maturation of the heart and its subsequent health and disease.


Subject(s)
Receptors, Glucocorticoid/metabolism , Receptors, Mineralocorticoid/metabolism , Animals , Heart Diseases/metabolism , Humans , Myocytes, Cardiac/metabolism , Receptors, Glucocorticoid/genetics , Receptors, Mineralocorticoid/genetics , Signal Transduction/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...